SELECT PUBLICATIONS

Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42. Abstract

Coiffier B et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors. Proc ASCO 2003;Abstract 2395.

Coiffier B et al. Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study. Proc ASH 2001;Abstract 3025.

Habermann TM et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update. Proc ASH 2004;Abstract 127.

Pfreundschuh MG et al. Randomized Intergroup trial of first line treatment for patients ≤ 60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOPlike regimen with or without the anti-CD antibody rituximab — Early stopping after the first interim analysis. Presentation. ASCO 2004a;Abstract 6500.

Pfreundschuh M et al. First analysis of the completed Mabthera International (MInt) Trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcomes of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Presentation. ASH 2004b;Abstract 157.

Pfreundschuh M et al; German High-Grade Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 2004c;104(3):626-33. Abstract

Pfreundschuh M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004d;104(3):634-41. Abstract

Reyes F et al; Groupe d’Etude des Lymphomes de l’Adulte (GELA). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352(12):1197-205. Abstract

Van Oers MHJ et al. Chimeric anti-CD20 monoclonal antibody (rituximab; MabThera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: A Phase III randomized Intergroup clinical trial. Proc ASH 2004;Abstract 586.